IN-ARMOR is a granted project by the European Health and Digital Executive Agency (HADEA) under HORIZON-HLTH-2022-DISEASE-06-two-stage call. Its target objective is to introduce a novel class of immune system inducers able to enhance the body’s own innate microbial defense mechanisms to combat antimicrobial resistance (AMR) and reduce the incidence of the 13 listed most dangerous infections (including 2 of the top 3 priority-1 infections).
IN-ARMOR will optimize an already developed drug platform using Computer Aided Drug Design, and in-silico approaches, in tandem with a nanotech-based drug delivery system for the first target indication. The developed therapy will be pre-clinically validated for safety and efficacy in-vitro and in vivo to complete all Investigational Medicinal Product requirements.
Upon completion, IN-ARMOR will be prepared for clinical validation. Upon commercialization, IN-ARMOR could potentially save more than 4Mn lives worldwide and result in the significant burden reduction of antibiotic development with long-term cost reduction impact of €107Bn, whilst reducing the global disease burden by 96.84Mn DALYs (total disease burden -enteric infections in 2019 in Disability-Adjusted Life Years-DALYs).